Keryx Biopharmaceuticals Inc. (KERX) Trading Down 3.3%
Shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) dropped 3.3% during trading on Wednesday . The company traded as low as $4.06 and last traded at $4.11, with a volume of 1,086,312 shares changing hands. The stock had previously closed at $4.25.
KERX has been the subject of a number of research reports. Brean Capital cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, August 2nd. FBR & Co reaffirmed an “outperform” rating and set a $13.00 target price on shares of Keryx Biopharmaceuticals in a report on Tuesday, May 17th. Cowen and Company reaffirmed a “neutral” rating on shares of Keryx Biopharmaceuticals in a report on Wednesday, August 3rd. Maxim Group cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Finally, Zacks Investment Research cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $7.75.
The company’s market capitalization is $434.17 million. The firm has a 50-day moving average price of $5.45 and a 200 day moving average price of $5.34.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by $0.14. During the same period in the prior year, the firm earned ($0.26) earnings per share. The firm earned $9.30 million during the quarter, compared to analyst estimates of $8.60 million. The company’s revenue for the quarter was up 272.0% on a year-over-year basis. Equities research analysts expect that Keryx Biopharmaceuticals Inc. will post ($1.24) EPS for the current year.
In other news, CFO Scott A. Holmes sold 4,935 shares of the stock in a transaction that occurred on Friday, July 29th. The stock was sold at an average price of $7.36, for a total value of $36,321.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.